secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0000950170-21-005288
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences CEO Matt Plavan resigns, appoints Kevin Comcowich as interim CEO
--------------------------------------------------------------------------------

- Matt Plavan resigned as CEO, President, and board member, effective Dec 31, 2021.
- Kevin Comcowich appointed interim CEO effective Jan 1, 2022; will remain board chair.
- Comcowich to receive $30,833/month; Plavan severance: $61,666 on Jan 1 & Feb 1, $143,278 on Mar 1, 2022.
- Plavan's stock options fully vest Dec 31, 2021, exercisable until June 30, 2024.
- Related party: Company leases land from Comcowich's entity for hemp; total lease payments $240,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017021005288/0000950170-21-005288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017021005288/rkda-20211214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-005288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer